Veracyte, Inc.
VCYT
$46.16
-$0.23-0.50%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 495.14M | 479.13M | 463.39M | 445.76M | 425.33M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 495.14M | 479.13M | 463.39M | 445.76M | 425.33M |
| Cost of Revenue | 145.06M | 141.11M | 136.99M | 136.07M | 128.38M |
| Gross Profit | 350.08M | 338.02M | 326.41M | 309.70M | 296.96M |
| SG&A Expenses | 214.07M | 210.48M | 207.01M | 203.88M | 202.00M |
| Depreciation & Amortization | 13.43M | 13.90M | 14.40M | 14.85M | 15.80M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 441.81M | 436.33M | 429.45M | 424.09M | 414.86M |
| Operating Income | 53.33M | 42.80M | 33.95M | 21.68M | 10.47M |
| Income Before Tax | 31.01M | 28.97M | 35.08M | 25.74M | -8.17M |
| Income Tax Expenses | 693.00K | 2.63M | 2.03M | 1.61M | 1.10M |
| Earnings from Continuing Operations | 30.32 | 26.34 | 33.05 | 24.14 | -9.27 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 30.32M | 26.34M | 33.05M | 24.14M | -9.27M |
| EBIT | 53.33M | 42.80M | 33.95M | 21.68M | 10.47M |
| EBITDA | 75.70M | 65.78M | 57.18M | 45.14M | 34.01M |
| EPS Basic | 0.39 | 0.34 | 0.43 | 0.31 | -0.14 |
| Normalized Basic EPS | 0.53 | 0.47 | 0.37 | 0.25 | 0.21 |
| EPS Diluted | 0.38 | 0.33 | 0.41 | 0.30 | -0.15 |
| Normalized Diluted EPS | 0.52 | 0.46 | 0.36 | 0.25 | 0.21 |
| Average Basic Shares Outstanding | 312.75M | 311.04M | 309.19M | 305.92M | 301.42M |
| Average Diluted Shares Outstanding | 318.04M | 316.82M | 315.59M | 310.29M | 303.49M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |